Injury primes mutation-bearing astrocytes for dedifferentiation in later life

Curr Biol. 2023 Mar 27;33(6):1082-1098.e8. doi: 10.1016/j.cub.2023.02.013. Epub 2023 Feb 24.

Abstract

Despite their latent neurogenic potential, most normal parenchymal astrocytes fail to dedifferentiate to neural stem cells in response to injury. In contrast, aberrant lineage plasticity is a hallmark of gliomas, and this suggests that tumor suppressors may constrain astrocyte dedifferentiation. Here, we show that p53, one of the most commonly inactivated tumor suppressors in glioma, is a gatekeeper of astrocyte fate. In the context of stab-wound injury, p53 loss destabilized the identity of astrocytes, priming them to dedifferentiate in later life. This resulted from persistent and age-exacerbated neuroinflammation at the injury site and EGFR activation in periwound astrocytes. Mechanistically, dedifferentiation was driven by the synergistic upregulation of mTOR signaling downstream of p53 loss and EGFR, which reinstates stemness programs via increased translation of neurodevelopmental transcription factors. Thus, our findings suggest that first-hit mutations remove the barriers to injury-induced dedifferentiation by sensitizing somatic cells to inflammatory signals, with implications for tumorigenesis.

Keywords: EGFR signaling; aging; astrocytes; brain injury; dedifferentiation; mTOR signaling; neural stem cells; neuroinflammation; p53.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes* / pathology
  • ErbB Receptors / genetics
  • Mutation
  • Neural Stem Cells*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Tumor Suppressor Protein p53
  • ErbB Receptors